Trusted Resource for Clinical Trials, Protocols & Progress
The Indian regulatory environment for clinical trials has evolved significantly, particularly with the introduction of the NDCTR in March 2019. This unified framework replaced the earlier Schedule Y under the Drugs and Cosmetics Rules and introduced defined approval timelines, ethical safeguards, compensation guidelines, and transparency requirements.
Click to read the full article.
The evolution of EC oversight in India has been driven by the need to bring ethical governance in line with international standards. Major regulatory reforms were prompted by global scrutiny, increased clinical trial activity, and ethical lapses reported in media and inspections.
Click to read the full article.
GCP inspections in India are governed by the New Drugs and Clinical Trials Rules (NDCTR), 2019, which empower CDSCO to conduct audits and inspections of clinical trial sites, sponsors, and ethics committees. These inspections are carried out to verify GCP compliance, review documentation, ensure protection of trial participants, and validate reported trial data.
Click to read the full article.
The ICMR, under the Department of Health Research, Ministry of Health and Family Welfare, is India’s apex body for formulating ethical guidelines in biomedical research. The ICMR guidelines are recognized by national regulators such as CDSCO and institutional ECs across India. These guidelines are revised periodically to incorporate global ethical standards, technological advancements, and socio-cultural realities.
Click to read the full article.
India’s compensation rules were introduced following several public interest litigations and media reports in the early 2010s that highlighted ethical lapses and lack of financial protection for trial participants. In response, the CDSCO introduced draft rules in 2013, which later culminated in the legally binding NDCTR 2019. These rules provide a structured process for managing trial-related injury, insurance requirements, and compensation determination.
Click to read the full article.
Bioavailability refers to the rate and extent to which the active pharmaceutical ingredient (API) becomes available at the site of action. Bioequivalence refers to the absence of a significant difference in bioavailability between two pharmaceutical products when administered at the same molar dose under similar conditions.
Click to read the full article.
The New Drugs and Clinical Trials Rules (NDCTR), 2019 mandate ethical and scientifically sound recruitment practices irrespective of the location. The Indian Council of Medical Research (ICMR) 2017 Guidelines also emphasize culturally sensitive and community-inclusive recruitment strategies. Clinical trial sponsors are expected to ensure equitable access to trial opportunities, including underserved populations in Tier-2 and rural settings, without compromising ethical standards.
Click to read the full article.
India’s clinical trial oversight is centrally managed by CDSCO, under the Ministry of Health and Family Welfare. Multinational trials require approval from the DCGI (Drugs Controller General of India) and local Ethics Committees. Since the implementation of NDCTR 2019, India has streamlined its approval process for MCTs, introducing timelines, clarity in responsibilities, and greater transparency.
Click to read the full article.
The CTRI was launched in July 2007 by the Indian Council of Medical Research (ICMR) through the National Institute of Medical Statistics (NIMS) with technical support from the WHO. It was designed to serve as a free, online, searchable database for all types of clinical studies conducted in India, including interventional, observational, and bioequivalence trials.
Click to read the full article.
Historically, clinical research in India was dominated by industry-sponsored trials. However, with growing policy support and capacity-building programs, academic institutions have emerged as key players. Recognizing their value, the NDCTR 2019 and CDSCO have provided simplified pathways for IITs while maintaining ethical and scientific rigor. The ICMR guidelines emphasize the responsibility of academic sites in protecting human subjects and maintaining data integrity.
Click to read the full article.
